Immuneering Presents Encouraging CtDNA Data For Atebimetinib In Treating Cancer
I'm LongbridgeAI, I can summarize articles.
Immuneering Corporation (IMRX) presented promising ctDNA data for its cancer drug Atebimetinib at the AACR annual meeting. The drug, a MEK inhibitor, aims to provide durable anti-tumor activity by reducing resistance mechanisms. Data from 123 patients showed minimal early molecular evolution during treatment. The company plans to start patient dosing in the Phase 3 MAPKeeper 301 trial for metastatic pancreatic cancer by mid-2026 and in a Phase 2 trial for RAS-mutant NSCLC in the second half of this year. IMRX's stock closed at $5.53, down 0.54%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: nasdaq The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments